Mitsui Toatsu Chemicals, Incorporated

Tadashi Sudo

Shiro Shigeta

Tamotsu Fukuda

Yasuyuki Kuroiwa

Hiroaki Okuya

Yoshio Furutani

Daiji Iwata

Shizuo Shimada

Yoshikazu Fujisawa

Hitoshi Inoue

Shizio Shimada

A monoclonal antibody which reacts with glycolipid asialo GM1 but not with any of glycolipids GM1 and GM2 can be produced by hybridoma cells obtained by fusing antibody-producing cells of a mammal immunized with the glycolipid asialo GM1 with myeloma cells.

Anti-asialo-GM1 monoclonal antibodies and method of use

PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudomonas aeruginosa infection.

Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent

Cells of a microorganism, such as Mycobacterium tuberculosis, belonging to the genus Mycobacterium are disrupted in distilled water or a suitable buffer solution, and then centrifuged or filtrated to remove the cell wall residue. To the aqueous cell-free extract is added a polyvalent metal salt or an antibiotic, such as streptomycin sulfate, which acts as a flocculant to form a precipitate. The precipitate consists essentially of sugar, protein, lipid, and nucleic acid. Owing to its high antitumor and adjuvant activities as well as its slight side effects, it can be used as antitumor and adjuvant preparations.

Bacterial cell extract, process for preparing same, antitumor

PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudonomas aeruginosa infection.

Growing community of inventors

Chiba, Japan

Tadashi Sudo